Donna Feild
YOU?
Author Swipe
View article: The Financial Toxicity Tumor Board: 5-Year Update on Practice and a Guide to Implementation
The Financial Toxicity Tumor Board: 5-Year Update on Practice and a Guide to Implementation Open
Background: Financial toxicity has been increasingly recognized as a major driver of negative outcomes for patients with cancer, with prior interventions focused primarily on patient-level support. The Financial Toxicity Tumor Board (FTTB)…
View article: Levine Cancer Institute Financial Toxicity Tumor Board: A Potential Solution to an Emerging Problem
Levine Cancer Institute Financial Toxicity Tumor Board: A Potential Solution to an Emerging Problem Open
PURPOSE: Fiscal distress or “financial toxicity,” in which patients experience challenges in paying for treatment, are becoming dominant problems for patients with cancer because of burgeoning health care costs and strategies implemented b…
View article: Filgrastim Plus Fixed-Dose Plerixafor is Cost-Effective in Peripheral Blood Hematopoietic Cell Mobilization in Patients with Multiple Myeloma
Filgrastim Plus Fixed-Dose Plerixafor is Cost-Effective in Peripheral Blood Hematopoietic Cell Mobilization in Patients with Multiple Myeloma Open
The addition of plerixafor to filgrastim-based mobilization rapidly and effectively improves the yield and efficiency of peripheral blood hematopoietic cell mobilization. However, the cost of plerixafor has limited its widespread use. At o…